ToeFX Light Therapy for Chronic Venous Leg Ulcers
Adjunctive ToeFX Photodynamic Therapy for Chronic Venous Leg Ulcers: A Single-Arm, Open-Label Pilot Feasibility Study
Chronic venous leg ulcers can be painful and prone to infection. They can significantly limit a patient's function, mobility and quality of life.
A major contributor to delayed ulcer healing is persistent bacteria. Treatments that can penetrate the bacteria's protective outer shield to kill and clear the bacteria are important for helping ulcers heal more quickly.
The purpose of this pilot study is to test a topical study treatment (called ClearToe Serum®) plus two types of light (red and blue-purple light) in the treatment of chronic venous ulcers.
This is an open-label single-arm pilot study. All participants will receive the test treatment as well as standard or care treatment for their chronic venous ulcer. Participants will receive study treatments one per week for up to 12 weeks, or until their ulcer is healed.
The main objectives are to assess adherence to the one-per-week study treatments, and to note any study device-related, study treatment-related, or serious adverse events, or adverse events that lead to stopping study treatment.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Chronic venous leg ulcers (VLUs) are a common and costly. They affect about 1% adults and are a significant burden to patients and the healthcare system. VLUs are often painful, malodorous, and prone to infection. They can have a big impact a patient's function, mobility, and quality of life. Standard of care (SOC) treatment, meaning the usual treatment, includes compression therapy, regular wound care (removing dead tissue, cleaning and dressing the wound), and infection management. Even with SOC treatment, about half of VLUs persist for months or years.
A major contributor to delayed healing is persistent bacterial infection, including bacteria that produce a biofilm, a protective covering resistant to many topical and systemic antibiotics. Strategies that can penetrate the biofilm to reduce local bacterial infection without contributing to antibiotic resistance are of particular interest in chronic wound management.
ToeFX has developed a non-thermal photodynamic therapy (PDT) platform that combines a methylene-blue-based photosensitizer (ClearToe® serum) with 660 nm light irradiation. Upon activation by light of the appropriate wavelength, the photosensitizer generates reactive oxygen species that are toxic to a broad range of bacteria but harmless for host tissue. This mechanism of photodynamic disinfection is well established in other clinical contexts, and the ToeFX platform is currently approved/registered for other indications. The ToeFX ClearToe® system is approved by Health Canada for the treatment of onychomycosis (toenail fungus). Its potential to reduce local bioburden and support a more favourable wound-healing environment has not yet been formally evaluated in venous leg ulcers.
This pilot study is intended to evaluate the feasibility (treatment adherence) and safety of ToeFX photodynamic therapy as an adjunct to SOC in a defined population of patients with chronic venous leg ulcers, while collecting preliminary clinical, wound-healing, and patient-reported outcome data to inform the design of a future, larger controlled trial.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Ahmed Kayssi, MD MSc FRCSC
- Número de telefone: (416) 691-2030
- E-mail: ahmed.kayssi@sunnybrook.ca
Locais de estudo
-
-
Ontario
-
Toronto, Ontario, Canadá, M4L 3Y3
- East Toronto Vascular Clinic
-
Contato:
- Ahmed Kayssi, MD MSc FRCSC
- Número de telefone: (416) 691-2030
- E-mail: ahmed.kayssi@sunnybrook.ca
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age 18 years or older
- Able to attend weekly visits for up to 12 weeks
- Chronic venous leg ulcer (CEAP C6) of the lower extremity
- Ulcer duration of 4 weeks or more
- Ulcer size between 1 cm² and 20 cm² at baseline
- Receiving standard-of-care compression therapy, or eligible to initiate it
- Able to provide informed consent and comply with study procedures
Exclusion Criteria:
- Wound location or anatomy not compatible with the ToeFX photodynamic therapy device
- Systemic infection (e.g., fever, sepsis, spreading cellulitis) or wound requiring systemic antibiotics
- Necrotic tissue over 25% of the wound bed, exposed bone or tendon, deep abscess, osteomyelitis or gangrene
- Severe ischemia (ABI below 0.5) or poorly controlled diabetes (HbA1c above 10%)
- Heavy exudate requiring negative-pressure wound therapy
- Known photosensitivity or allergy to methylene blue or light-based therapies
- Immunosuppressive therapy, radiation or chemotherapy within the past 3 months, or active malignancy
- Pregnancy or lactation
- Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
- Participation in another interventional study within 30 days of screening
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Viabilidade do dispositivo
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: ToeFX Treatment
Weekly ToeFX treatment of venous leg ulcer up to 12 weeks or wound closure |
Non-thermal photodynamic therapy platform that combines a methylene-blue-based photosensitizer ( ClearToe® serum) with 660 nm light irradiation
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Treatment adherence
Prazo: Baseline through Visit 12/ end of treatment (up to 12 weeks)
|
Percentage of planned ToeFX treatment sessions completed per participant, and reasons for missed or discontinued sessions |
Baseline through Visit 12/ end of treatment (up to 12 weeks)
|
|
Safety: Adverse Events
Prazo: Baseline through Healing Confirmation Visit (up to 14 weeks)
|
Incidence and severity of adverse events (AEs), serious adverse events (SAEs), device-related AEs, treatment-related AEs, and study discontinuations due to AEs |
Baseline through Healing Confirmation Visit (up to 14 weeks)
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percent Change in Wound Area From Baseline
Prazo: Baseline, week 4, week 8, and week 12
|
Percent change in wound area (cm²) from baseline |
Baseline, week 4, week 8, and week 12
|
|
Complete wound epithelialization
Prazo: 12 weeks
|
Proportion of participants achieving complete epithelialization by Week 12, as assessed by clinician |
12 weeks
|
|
Time to complete wound healing
Prazo: 12 weeks
|
Time (days) from baseline to complete epithelialization |
12 weeks
|
|
Change in Bates-Jensen Wound Assessment Tool (BWAT) score
Prazo: Baseline to 12 weeks/ end of treatment
|
Change in wound bed characteristics measured using the BWAT |
Baseline to 12 weeks/ end of treatment
|
|
Change in pain score
Prazo: Baseline to 12 weeks/ end of treatment
|
Change in pain score (0-10 Numeric Rating Scale) |
Baseline to 12 weeks/ end of treatment
|
|
Change in health-related quality of life
Prazo: 12 weeks/ end of treatment
|
Change in EQ-5D-5L score |
12 weeks/ end of treatment
|
|
Patient satisfaction
Prazo: 12 weeks/ end of treatment
|
Patient-reported satisfaction with treatment measured by study-specific patient satisfaction questionnaire |
12 weeks/ end of treatment
|
|
Clinician feasibility
Prazo: 14 weeks or earlier if wound healing
|
Qualitative and operational observations on feasibility of integrating PDF into routine wound care workflow |
14 weeks or earlier if wound healing
|
|
Absolute Change in Wound Area From Baseline
Prazo: Baseline, week 4, week 8, and week 12
|
Absolute change in wound area (cm²) from baseline |
Baseline, week 4, week 8, and week 12
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Ahmed Kayssi, MD MSc FRCSC, East Toronto Vascular Clinic
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- PRO04244160_ToeFX
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
This is a small single-centre pilot study. Individual participant data will not be shared because of participant privacy considerations and the terms of the clinical trial agreement with the study funder. Data are de-identified using study IDs and stored with restricted access. Aggregate results will be published.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .